

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



天津泰達生物醫學工程股份有限公司
Tianjin TEDA Biomedical Engineering Company Limited
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 8189)

CHANGE OF CHIEF EXECUTIVE OFFICER

The board of directors (the “**Board**”) of Tianjin TEDA Biomedical Engineering Company Limited (the “**Company**”) hereby announces that Ms. Sun Li has resigned as chief executive officer of the Company (“**CEO**”) and will remain as the Chairman of the Board, executive director, Chairman of the nomination committee, member of the remuneration committee of the Company; and Mr. Yang Junmin is appointed as the new CEO of the Company, with effect from 1 February 2019.

RESIGNATION OF CHIEF EXECUTIVE OFFICER

Ms. Sun Li (“**Ms. Sun**”) has resigned as the CEO of the Company with effect from 1 February 2019, whose purpose is to achieve better corporate governance under the Code Provision A.2.1 of the Corporate Governance Code as set out in Appendix 15 of the GEM Listing Rules of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”). Hence, Ms. Sun, as Chairman of the Board, can dedicate more efforts and spend more time in deciding and dealing with the Company’s corporate policies and major matters. Ms. Sun Li will remain as the Chairman of the Board, executive director, Chairman of the nomination committee and member of the remuneration committee of the Company.

Ms. Sun has confirmed that, in relation to her resignation, she does not have any disagreement with the Board and that there is no other matter relating to her above resignation that needs to be brought to the attention of the shareholders of the Company and the Stock Exchange.

APPOINTMENT OF NEW CHIEF EXECUTIVE OFFICER

The Board has appointed Mr. Yang Junmin (“**Mr. Yang**”) to replace Ms. Sun as the CEO of the Company with effect from 1 February 2019.

The biographical details of Mr. Yang are set out below:

Mr. Yang, aged 53, graduated from Xi’an Foreign Language Institute in July 1990, majored in French Language, with a bachelor’s degree in French. Mr. Yang has engaged in the cultural exchanges and commercial cooperation between China and France for 29 years, and is engaged in the elderly care industry for seven years. He has extensive experience in internationally advanced operations, management, consulting and training of elderly care business. In 2013, he collaborated with the Caisse nationale de solidarité pour l’autonomie (CNSA) (法國養老基金理事會) and China Development Bank to organise the first session of Sino-French Elderly Care Cooperation Meeting in Beijing. From 2014 to 2018, he served as the executive president of China region of DOMUSVI, the third largest elderly care group in France, and had successfully established Xi’an Trade Union DOMUSVI Nursing Home (西安工會多慰護理院) in Xi’an, Shaanxi Province, the PRC in May 2017. The nursing home has 200 beds and were fully occupied in less than one year after its opening. Two Ministers of Health of French under different sessions visited the nursing home with good applause. The delegation of the State Council’s Medical and Nursing Research Group (中國國務院醫養結合考察組) and the Standardization Administration gave their high recognition. The project has successfully introduced the brand and standard process system of DOMUSVI, the world-renowned elderly care group in France, and trained a number of high quality management and operation teams. Since 2017 to date, he serves as the vice chairman of the Sino-French Aged Services Cooperative Association (法中養老服務合作協會). The association includes over 20 elderly care management operators, elderly care product development agencies, design companies for medical and elderly care institutions, elderly care training institutions and elderly care insurance and financial institution in France.

The Board believes that with his extensive working experience in the internationally advanced elderly care industry, Mr. Yang, as the CEO of the Company, can lead the Company to achieve a rapid and healthy development in our elderly care business.

After Mr. Yang is appointed as the CEO of the Company, his service agreement that entered into with the Company will commence on 1 February 2019 and expire on 31 December 2019. The agreement will be renewed after submission to the Board for approval. Mr. Yang is entitled to an annual emolument of RMB680,000. The remuneration of Mr. Yang is determined by reference to his duties and responsibilities in the Company and the prevailing market conditions.

Save as disclosed above, as at the date of this announcement, Mr. Yang (i) does not hold any other position with the Company or other members of the Company; (ii) does not have any relationship with any directors, senior management, substantial shareholders or controlling shareholders of the Company or any of their associates (as defined in the GEM Listing Rules); (iii) does not hold any shares of the Company (within the meaning of the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong); and (iv) does not hold any position in other companies for the last three years of which their securities are listed in Hong Kong or any other overseas securities markets, and does not have any other major appointments or professional qualifications.

Save as disclosed above, Mr. Yang confirmed there is no information in relation to Mr. Yang or his appointment which is required to be disclosed pursuant to Rule 17.50(2)(h) to (v) of GEM Listing Rules, and there is no other matter that needs to be brought to the attention of the shareholders of the Company.

The Board would like to take this opportunity to welcome Mr. Yang to become the CEO of the Company.

By order of the Board
Tianjin TEDA Biomedical Engineering Company Limited
Sun Li
Chairman

Tianjin, the PRC

1 February 2019

As at the date of this announcement, the executive directors of the Company are Ms. Sun Li, Mr. Hao Zhihui and Mr. He Xin; the non-executive directors of the Company are Mr. Cao Aixin, Dr. Li Ximing and Ms. Gai Li; the independent non-executive directors of the Company are Mr. Li Xudong, Mr. Wang Yongkang and Ms. Gao Chun.

This announcement, for which the directors are willing to collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief that the information contained in this announcement is accurate and complete in all material respects and is not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the GEM website at www.hkgem.com on the “Latest Company Announcements” page for 7 days from the date of its posting, and it will also be published and remain on the website of the Company at www.bioteda.com.